ELI LILLY & Co LLY Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0000059478-25-000132
cik 59478
name ELI LILLY & CO
sic 2834
countryba US
stprba IN
cityba INDIANAPOLIS
zipba 46285
bas1 LILLY CORPORATE CTR
bas2 DROP CODE 1094
baph 3172762000
countryma US
stprma IN
cityma INDIANAPOLIS
zipma 46285
mas1 LILLY CORPORATE CENTER
mas2 DROP CODE 1094
countryinc US
stprinc IN
ein 350470950
former LILLY ELI & CO
changed 19941024
afs 1-LAF
wksi 0
fye 1231
form 10-Q
period 20250331
fy 2025
fp Q1
filed 20250501
accepted 2025-05-01 11:30:00.0
prevrpt 0
detail 1
instance lly-20250331_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0000059478-25-000132 20250331 Accounts Receivable Net Current 12036600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 11789000000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Assets 78714900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 3268400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Common Stock Shares Issued 950768000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20250331 Common Stock Shares Issued 948095000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20240331 Cost Of Goods And Services Sold 1673500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Cost Of Sales Operating Expenses And Other Net 9272400000.0000 USD 1 0000059478-25-000132
0000059478-25-000132 20250331 Depreciation Depletion And Amortization 462800000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Depreciation Depletion And Amortization 462800000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20241231 Long Term Investments 3215900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Minority Interest 79500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Net Cash Provided By Used In Financing Activities -311300000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Net Income Loss 2759300000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20241231 Other Assets Current 111400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Other Assets Noncurrent 6074900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 27500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 547300000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20240331 Other Operating Activities Cash Flow Statement 298600000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Payments For Proceeds From Other Investing Activities 48200000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Payments For Repurchase Of Common Stock 1200000000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent 1300500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Research And Development Expense Excluding Acquired In Process Cost 1670700000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment; Product Or Service= Late Stage;
0000059478-25-000132 20250331 Research And Development Expense Excluding Acquired In Process Cost 990000000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment; Product Or Service= Early Stage;
0000059478-25-000132 20240331 Revenues 811700000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Oncology;
0000059478-25-000132 20240331 Revenues 257000000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Taltz;
0000059478-25-000132 20240331 Revenues 412100000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Verzenio;
0000059478-25-000132 20240331 Revenues 50100000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Other Immunology;
0000059478-25-000132 20250331 Revenues 12728500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Revenues 82800000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Neuroscience;
0000059478-25-000132 20250331 Revenues 285400000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Taltz;
0000059478-25-000132 20250331 Revenues 6576700000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Cardiometabolic Health;
0000059478-25-000132 20250331 Revenues 101600000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Other Immunology;
0000059478-25-000132 20241231 Sales Rebates And Discounts 11539300000.0000 USD 0 0000059478-25-000132
0000059478-25-000132 20240331 Selling General And Administrative Expense 1952200000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Short Term Investments 127400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20231231 Stockholders Equity -1819000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000059478-25-000132 20240331 Stockholders Equity -2658700000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0000059478-25-000132 20241231 Stockholders Equity 14192100000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Stockholders Equity 278100000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0000059478-25-000132 20241231 Stockholders Equity -31700000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0000059478-25-000132 20241231 Stockholders Equity -4321900000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20241231 Stockholders Equity -2389600000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000059478-25-000132 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 7250400000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 593600000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 91800000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000059478-25-000132 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 10312300000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -4321900000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 13545000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -49500000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common; As of March 31, 2025, there was $13.80 billion remaining under our $15.00 billion share repurchase program authorized in December 2024.
0000059478-25-000132 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 592600000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 15099500000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20240331 Stock Issued During Period Shares Employee Stock Purchase Plans 987000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20250331 Stock Issued During Period Value Employee Stock Purchase Plan -683000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20250331 Treasury Stock Shares Acquired 1359000.0000 shares 1 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20250331 Cash And Cash Equivalents At Carrying Value 3093300000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Accounts Receivable Net Current 11005700000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Accrued Income Taxes Noncurrent 4060900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Accumulated Other Comprehensive Income Loss Net Of Tax -4321900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax -3774600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Allowance For Doubtful Accounts Receivable Current 14900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Assets Current 32739700000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Common Stock Shares Held In Employee Trust 3013200000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Common Stock Value 592600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Comprehensive Income Net Of Tax 3306600000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Dividends Payable Current 0.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Earnings Per Share Basic 2.4900 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Earnings Per Share Diluted 3.0600 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Gain Loss On Investments -149100000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Income Tax Expense Benefit 4300000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0000059478-25-000132 20250331 Increase Decrease In Deferred Income Taxes 391600000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Inventory Net 9311000000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Liabilities And Stockholders Equity 78714900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Long Term Investments 3215900000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure;
0000059478-25-000132 20250331 Long Term Investments 3222700000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure;
0000059478-25-000132 20240331 Net Income Loss 2242900000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Net Income Loss 2242900000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20250331 Other Liabilities Current 3769800000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Payments For Proceeds From Other Investing Activities -39300000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Proceeds From Payments For Other Financing Activities -389800000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Profit Loss 23000000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0000059478-25-000132 20240331 Revenues 363900000.0000 USD 1 us-gaap/2024 Geographical= J P;
0000059478-25-000132 20240331 Revenues 424100000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Other Cardiometabolic Health;
0000059478-25-000132 20240331 Revenues 196200000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Other Product Total;
0000059478-25-000132 20240331 Revenues 374400000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Trulicity;
0000059478-25-000132 20240331 Revenues 347100000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Taltz;
0000059478-25-000132 20240331 Revenues 517400000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Zepbound;
0000059478-25-000132 20240331 Revenues 834000000.0000 USD 1 us-gaap/2024 Product Or Service= Immunology;
0000059478-25-000132 20240331 Revenues 1050300000.0000 USD 1 us-gaap/2024 Product Or Service= Verzenio;
0000059478-25-000132 20250331 Revenues 388200000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Other Oncology;
0000059478-25-000132 20250331 Revenues 770500000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Trulicity;
0000059478-25-000132 20250331 Revenues 657600000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Verzenio;
0000059478-25-000132 20250331 Revenues 272100000.0000 USD 1 us-gaap/2024 Product Or Service= Neuroscience;
0000059478-25-000132 20250331 Revenues 2311900000.0000 USD 1 us-gaap/2024 Product Or Service= Zepbound;
0000059478-25-000132 20250331 Selling General And Administrative Expense 2468800000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Short Term Investments 154800000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20231231 Stockholders Equity -4327000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20241231 Stockholders Equity -2178700000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0000059478-25-000132 20250331 Stockholders Equity 253800000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0000059478-25-000132 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -4299500000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -32700000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20250331 Stockholders Equity Other 5600000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20240331 Stock Issued During Period Value Employee Stock Purchase Plan 600000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20250331 Stock Issued During Period Value Share Based Compensation 153700000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20250331 Taxes Payable Current 6175700000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Treasury Stock Common Shares 365000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20250331 Treasury Stock Retired Cost Method Amount 1199200000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20250331 Other Liabilities Noncurrent 2288400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Increase Decrease In Other Operating Capital Net 1751200000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Increase Decrease In Other Operating Capital Net 3364200000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Cash And Cash Equivalents At Carrying Value 3268400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 3093300000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -175100000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0000059478-25-000132 20250331 Common Stock Shares Held In Employee Trust 3013200000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Comprehensive Income Net Of Tax 2270400000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Cost Of Goods And Services Sold 2224200000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Depreciation Depletion And Amortization 400600000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20240331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -35500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 131900000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Income Tax Expense Benefit 293200000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 27500000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20250331 Other Receivables Net Current 1966600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Payments Of Dividends 1169200000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Payments To Acquire Other Property Plant And Equipment 986300000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Proceeds From Payments For Other Financing Activities -686300000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Proceeds From Repayments Of Short Term Debt -1848700000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Proceeds From Sale And Maturity Of Other Investments 71600000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Profit Loss 47900000.0000 USD 1 us-gaap/2024 Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0000059478-25-000132 20241231 Property Plant And Equipment Net 17102400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Property Plant And Equipment Net 18474100000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Research And Development Asset Acquired Other Than Through Business Combination Written Off 110500000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20250331 Research And Development Asset Acquired Other Than Through Business Combination Written Off 1571700000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Restructuring Settlement And Impairment Provisions 0.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Retained Earnings Accumulated Deficit 13545000000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Revenues 376200000.0000 USD 1 us-gaap/2024 Geographical= C N;
0000059478-25-000132 20240331 Revenues 1403000000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Cardiometabolic Health;
0000059478-25-000132 20240331 Revenues 0.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Zepbound;
0000059478-25-000132 20240331 Revenues 163200000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Neuroscience;
0000059478-25-000132 20240331 Revenues 638200000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Verzenio;
0000059478-25-000132 20240331 Revenues 971500000.0000 USD 1 us-gaap/2024 Product Or Service= Collaborationand Other Revenue;
0000059478-25-000132 20240331 Revenues 686500000.0000 USD 1 us-gaap/2024 Product Or Service= Jardiance;
0000059478-25-000132 20240331 Revenues 7796500000.0000 USD 1 us-gaap/2024 Product Or Service= Product;
0000059478-25-000132 20250331 Revenues 450800000.0000 USD 1 us-gaap/2024 Geographical= C N;
0000059478-25-000132 20250331 Revenues 402200000.0000 USD 1 us-gaap/2024 Geographical= J P;
0000059478-25-000132 20250331 Revenues 4239100000.0000 USD 1 us-gaap/2024 Geographical= Non Us;
0000059478-25-000132 20250331 Revenues 2631400000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Cardiometabolic Health;
0000059478-25-000132 20250331 Revenues 9208100000.0000 USD 1 us-gaap/2024 Product Or Service= Cardiometabolic Health;
0000059478-25-000132 20250331 Revenues 1014400000.0000 USD 1 us-gaap/2024 Product Or Service= Jardiance;
0000059478-25-000132 20250331 Revenues 1947500000.0000 USD 1 us-gaap/2024 Product Or Service= Oncology;
0000059478-25-000132 20250331 Revenues 1158900000.0000 USD 1 us-gaap/2024 Product Or Service= Verzenio;
0000059478-25-000132 20250331 Selling General And Administrative Expense 2468800000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20250331 Share Based Compensation 153700000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20231231 Stockholders Equity -2697300000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0000059478-25-000132 20240331 Stockholders Equity -30900000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0000059478-25-000132 20250331 Stockholders Equity 15764800000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Stockholders Equity -3774600000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -3774600000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 6910000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -3013200000.0000 USD 0 us-gaap/2024 Equity Components= Trust For Benefit Of Employees;
0000059478-25-000132 20241231 Treasury Stock Common Value 49500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Treasury Stock Shares Retired 1359000.0000 shares 1 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20240331 Weighted Average Number Of Diluted Shares Outstanding 903800000.0000 shares 1 us-gaap/2024
0000059478-25-000132 20250331 Accounts Payable Current 3442000000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Additional Paid In Capital Common Stock 7439300000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Assets 89388800000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Debt Current 5117100000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Earnings Per Share Diluted 2.4800 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Income Tax Expense Benefit 696800000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Liabilities Noncurrent 43473900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Net Cash Provided By Used In Investing Activities -1177600000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 71600000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0000059478-25-000132 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -78000000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000059478-25-000132 20241231 Other Liabilities Current 3935000000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Payments For Repurchase Of Common Stock 0.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Profit Loss -5100000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000059478-25-000132 20240331 Research And Development Asset Acquired Other Than Through Business Combination Written Off 110500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Research And Development Asset Acquired Other Than Through Business Combination Written Off 1571700000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20240331 Research And Development Expense Excluding Acquired In Process Cost 2522800000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Revenues 8768000000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Revenues 3073700000.0000 USD 1 us-gaap/2024 Geographical= Non Us;
0000059478-25-000132 20240331 Revenues 892900000.0000 USD 1 us-gaap/2024 Geographical= Rest Of World;
0000059478-25-000132 20240331 Revenues 5694400000.0000 USD 1 us-gaap/2024 Geographical= U S;
0000059478-25-000132 20240331 Revenues 397200000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Immunology;
0000059478-25-000132 20240331 Revenues 602100000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Other Cardiometabolic Health;
0000059478-25-000132 20240331 Revenues 389100000.0000 USD 1 us-gaap/2024 Product Or Service= Neuroscience;
0000059478-25-000132 20240331 Revenues 229900000.0000 USD 1 us-gaap/2024 Product Or Service= Other Immunology;
0000059478-25-000132 20240331 Revenues 517400000.0000 USD 1 us-gaap/2024 Product Or Service= Zepbound;
0000059478-25-000132 20250331 Revenues 2388700000.0000 USD 1 us-gaap/2024 Geographical= Europe;
0000059478-25-000132 20250331 Revenues 409700000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Other Cardiometabolic Health;
0000059478-25-000132 20250331 Revenues 997400000.0000 USD 1 us-gaap/2024 Geographical= Rest Of World;
0000059478-25-000132 20250331 Revenues 1045800000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Oncology;
0000059478-25-000132 20250331 Revenues 99500000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Other Product Total;
0000059478-25-000132 20250331 Revenues 370000000.0000 USD 1 us-gaap/2024 Product Or Service= Jardiance; Type Of Arrangement= One Time Payment;
0000059478-25-000132 20250331 Revenues 212900000.0000 USD 1 us-gaap/2024 Product Or Service= Other Product Total;
0000059478-25-000132 20240331 Selling General And Administrative Expense 1952200000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20240331 Stockholders Equity -1897000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000059478-25-000132 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 594200000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 7439300000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 592400000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20240331 Stockholders Equity Other 1300000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20240331 Stock Issued During Period Shares Employee Stock Purchase Plans -37000.0000 shares 1 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20250331 Stock Repurchase Program Remaining Authorized Repurchase Amount1 13800000000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Treasury Stock Common Shares 365000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20241231 Treasury Stock Common Shares 365000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20250331 Treasury Stock Retired Cost Method Amount -1200000000.0000 USD 1 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20240331 Weighted Average Number Of Shares Outstanding Basic 900800000.0000 shares 1 us-gaap/2024
0000059478-25-000132 20250331 Allowance For Doubtful Accounts Receivable Current 15500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 2818600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20231231 Common Stock Shares Issued 949781000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20250331 Cost Of Goods And Services Sold 2224200000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20240331 Cost Of Sales Operating Expenses And Other Net 6231900000.0000 USD 1 0000059478-25-000132
0000059478-25-000132 20250331 Debt Current 4016400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Deferred Income Tax Assets Net 8000600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Depreciation Depletion And Amortization 400600000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Earnings Per Share Basic 3.0700 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 2536100000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 20500000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0000059478-25-000132 20240331 Income Tax Expense Benefit 293200000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Intangible Assets Net Excluding Goodwill 6012200000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Liabilities Current 28376600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Liabilities Noncurrent 36066700000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Net Cash Provided By Used In Investing Activities -3352300000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Net Cash Provided By Used In Operating Activities 1665600000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Other Assets Noncurrent 5719700000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -2800000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0000059478-25-000132 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -24300000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0000059478-25-000132 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 566000000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000059478-25-000132 20241231 Other Receivables Net Current 2269700000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Payments To Acquire Other Investments 117100000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Prepaid Expense Current 14653900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Proceeds From Issuance Of Long Term Debt 6461000000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Proceeds From Repayments Of Short Term Debt -5204800000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Proceeds From Sale And Maturity Of Other Investments 70500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Profit Loss 16200000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0000059478-25-000132 20250331 Profit Loss 7000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000059478-25-000132 20250331 Restructuring Settlement And Impairment Provisions 35000000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Retained Earnings Accumulated Deficit 15099500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Revenues 436800000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Immunology;
0000059478-25-000132 20240331 Revenues 318300000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Jardiance;
0000059478-25-000132 20240331 Revenues 286200000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Mounjaro;
0000059478-25-000132 20240331 Revenues 998300000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Oncology;
0000059478-25-000132 20240331 Revenues 5493000000.0000 USD 1 us-gaap/2024 Product Or Service= Cardiometabolic Health;
0000059478-25-000132 20240331 Revenues 1806500000.0000 USD 1 us-gaap/2024 Product Or Service= Mounjaro;
0000059478-25-000132 20240331 Revenues 1026300000.0000 USD 1 us-gaap/2024 Product Or Service= Other Cardiometabolic Health;
0000059478-25-000132 20240331 Revenues 759700000.0000 USD 1 us-gaap/2024 Product Or Service= Other Oncology;
0000059478-25-000132 20250331 Revenues 704600000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Jardiance;
0000059478-25-000132 20250331 Revenues 1185900000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Mounjaro;
0000059478-25-000132 20250331 Revenues 901700000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Oncology;
0000059478-25-000132 20250331 Revenues 8489400000.0000 USD 1 us-gaap/2024 Geographical= U S;
0000059478-25-000132 20250331 Revenues 309800000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Jardiance;
0000059478-25-000132 20250331 Revenues 189300000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Neuroscience;
0000059478-25-000132 20250331 Revenues 1127300000.0000 USD 1 us-gaap/2024 Product Or Service= Collaborationand Other Revenue;
0000059478-25-000132 20250331 Sales Rebates And Discounts 11550300000.0000 USD 0 0000059478-25-000132
0000059478-25-000132 20240331 Stockholders Equity -4299500000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -4327000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000059478-25-000132 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 7009500000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 12553900000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 14271600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 79500000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000059478-25-000132 20250331 Stockholders Equity Other 4500000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000059478-25-000132 20250331 Treasury Stock Value Acquired Cost Method USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20250331 Accrued Income Taxes Noncurrent 5370500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Additional Paid In Capital Common Stock 6910000000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0000059478-25-000132 20241231 Common Stock Value 592400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Deferred Income Tax Assets Net 8573200000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Dividends Payable Current 1346300000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Employee Related Liabilities Current 2093900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Employee Related Liabilities Current 1113900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Income Tax Expense Benefit 6100000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0000059478-25-000132 20250331 Income Tax Expense Benefit 696800000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20241231 Intangible Assets Net Excluding Goodwill 6166300000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Liabilities And Stockholders Equity 89388800000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Net Cash Provided By Used In Operating Activities 1166000000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Other Liabilities Noncurrent 2178200000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Payments Of Dividends 1346300000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Payments To Acquire Other Investments 196700000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent 1315500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Profit Loss 32900000.0000 USD 1 us-gaap/2024 Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0000059478-25-000132 20240331 Revenues 8768000000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20240331 Revenues 1440700000.0000 USD 1 us-gaap/2024 Geographical= Europe;
0000059478-25-000132 20240331 Revenues 225900000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Neuroscience;
0000059478-25-000132 20240331 Revenues 4090000000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Cardiometabolic Health;
0000059478-25-000132 20240331 Revenues 368200000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Jardiance;
0000059478-25-000132 20240331 Revenues 1081900000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Trulicity;
0000059478-25-000132 20250331 Revenues 400400000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Other Oncology;
0000059478-25-000132 20250331 Revenues 2305400000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Zepbound;
0000059478-25-000132 20250331 Revenues 3841800000.0000 USD 1 us-gaap/2024 Product Or Service= Mounjaro;
0000059478-25-000132 20250331 Revenues 1095200000.0000 USD 1 us-gaap/2024 Product Or Service= Trulicity;
0000059478-25-000132 20231231 Stockholders Equity 215500000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0000059478-25-000132 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -44200000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -3013200000.0000 USD 0 us-gaap/2024 Equity Components= Trust For Benefit Of Employees;
0000059478-25-000132 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 15846800000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 82000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000059478-25-000132 20240331 Stock Issued During Period Value Employee Stock Purchase Plan -400300000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20250331 Stock Issued During Period Value Employee Stock Purchase Plan 1000000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20240331 Stock Issued During Period Value Share Based Compensation 159400000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000059478-25-000132 20250331 Stock Repurchase Program Authorized Amount1 15000000000.0000 USD 0 srt/2024
0000059478-25-000132 20241231 Taxes Payable Current 1116400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Nonoperating Income Expense -239000000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Accounts Payable Current 3228600000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 12146900000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -358400000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Cost Of Goods And Services Sold 1673500000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20240331 Gain Loss On Investments 15800000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 29100000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest; Reclassification Out Of Accumulated Other Comprehensive Income= Reclassification Out Of Accumulated Other Comprehensive Income;
0000059478-25-000132 20240331 Increase Decrease In Deferred Income Taxes 279000000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Inventory Net 7589200000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Liabilities Current 30068100000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Long Term Debt Noncurrent 34499500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Long Term Investments 3222700000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Net Cash Provided By Used In Financing Activities 1379700000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Nonoperating Income Expense 27100000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 38600000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0000059478-25-000132 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -4700000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0000059478-25-000132 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 8400000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0000059478-25-000132 20250331 Other Operating Activities Cash Flow Statement 324800000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Payments To Acquire In Process Research And Development 96500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Prepaid Expense Current 8340500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Profit Loss 2242900000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20250331 Research And Development Expense Excluding Acquired In Process Cost 2733700000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Revenues 179800000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Other Immunology;
0000059478-25-000132 20240331 Revenues 399600000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Other Oncology;
0000059478-25-000132 20240331 Revenues 1520400000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Mounjaro;
0000059478-25-000132 20240331 Revenues 45700000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Other Product Total;
0000059478-25-000132 20240331 Revenues 1810000000.0000 USD 1 us-gaap/2024 Product Or Service= Oncology;
0000059478-25-000132 20240331 Revenues 604100000.0000 USD 1 us-gaap/2024 Product Or Service= Taltz;
0000059478-25-000132 20240331 Revenues 1456300000.0000 USD 1 us-gaap/2024 Product Or Service= Trulicity;
0000059478-25-000132 20250331 Revenues 12728500000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20250331 Revenues 113300000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Other Product Total;
0000059478-25-000132 20250331 Revenues 324700000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Trulicity;
0000059478-25-000132 20250331 Revenues 578100000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Immunology;
0000059478-25-000132 20250331 Revenues 2655900000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Mounjaro;
0000059478-25-000132 20250331 Revenues 476500000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Taltz;
0000059478-25-000132 20250331 Revenues 788600000.0000 USD 1 us-gaap/2024 Product Or Service= Other Oncology;
0000059478-25-000132 20240331 Share Based Compensation 159400000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Stockholders Equity -2181500000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0000059478-25-000132 20250331 Stockholders Equity -23300000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0000059478-25-000132 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -3013200000.0000 USD 0 us-gaap/2024 Equity Components= Trust For Benefit Of Employees;
0000059478-25-000132 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -3013200000.0000 USD 0 us-gaap/2024 Equity Components= Trust For Benefit Of Employees;
0000059478-25-000132 20250331 Treasury Stock Value Acquired Cost Method 1200000000.0000 USD 1 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20231231 Treasury Stock Common Shares 402000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20250331 Weighted Average Number Of Diluted Shares Outstanding 900600000.0000 shares 1 us-gaap/2024
0000059478-25-000132 20250331 Weighted Average Number Of Shares Outstanding Basic 898700000.0000 shares 1 us-gaap/2024
0000059478-25-000132 20241231 Assets 78714900000.0000 USD 0 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20250331 Assets 89388800000.0000 USD 0 us-gaap/2024 Business Segments= Reportable Segment;
0000059478-25-000132 20250331 Assets Current 41261200000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 2460200000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20241231 Common Stock Shares Issued 947903000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20241231 Goodwill 5770300000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Goodwill 5770500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 3456100000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20241231 Long Term Debt Noncurrent 28527100000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Minority Interest 82000000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Net Income Loss 2759300000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Other Assets Current 72400000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 547300000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Payments To Acquire In Process Research And Development 1757000000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Payments To Acquire Other Property Plant And Equipment 1509500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20240331 Proceeds From Issuance Of Long Term Debt 6452500000.0000 USD 1 us-gaap/2024
0000059478-25-000132 20250331 Profit Loss 2759300000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000059478-25-000132 20240331 Research And Development Expense Excluding Acquired In Process Cost 852100000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment; Product Or Service= Early Stage;
0000059478-25-000132 20250331 Research And Development Expense Excluding Acquired In Process Cost 1743700000.0000 USD 1 us-gaap/2024 Business Segments= Reportable Segment; Product Or Service= Late Stage;
0000059478-25-000132 20240331 Revenues 360100000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Other Oncology;
0000059478-25-000132 20240331 Revenues 241900000.0000 USD 1 us-gaap/2024 Product Or Service= Other Product Total;
0000059478-25-000132 20250331 Revenues 510000000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Immunology;
0000059478-25-000132 20250331 Revenues 224600000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Other Immunology;
0000059478-25-000132 20250331 Revenues 501300000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Verzenio;
0000059478-25-000132 20250331 Revenues 6500000.0000 USD 1 us-gaap/2024 Geographical= Non Us; Product Or Service= Zepbound;
0000059478-25-000132 20250331 Revenues 535100000.0000 USD 1 us-gaap/2024 Geographical= U S; Product Or Service= Other Cardiometabolic Health;
0000059478-25-000132 20250331 Revenues 1088000000.0000 USD 1 us-gaap/2024 Product Or Service= Immunology;
0000059478-25-000132 20250331 Revenues 944800000.0000 USD 1 us-gaap/2024 Product Or Service= Other Cardiometabolic Health;
0000059478-25-000132 20250331 Revenues 326100000.0000 USD 1 us-gaap/2024 Product Or Service= Other Immunology;
0000059478-25-000132 20250331 Revenues 11601200000.0000 USD 1 us-gaap/2024 Product Or Service= Product;
0000059478-25-000132 20250331 Revenues 761900000.0000 USD 1 us-gaap/2024 Product Or Service= Taltz;
0000059478-25-000132 20231231 Stockholders Equity -26200000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Net Unrealized Investment Gain Loss;
0000059478-25-000132 20240331 Stockholders Equity 287100000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0000059478-25-000132 20250331 Stockholders Equity -1823600000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000059478-25-000132 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 85200000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000059478-25-000132 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -49500000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20240331 Stockholders Equity Other 1500000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000059478-25-000132 20250331 Stock Issued During Period Shares Employee Stock Purchase Plans 1551000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20240331 Stock Issued During Period Value Employee Stock Purchase Plan 11500000.0000 USD 1 us-gaap/2024 Equity Components= Treasury Stock Common;
0000059478-25-000132 20250331 Treasury Stock Common Value 49500000.0000 USD 0 us-gaap/2024
0000059478-25-000132 20250331 Treasury Stock Retired Cost Method Amount 800000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0000059478-25-000132 20250331 Treasury Stock Shares Retired 1359000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Proceeds From Issuance Of Long Term Debt us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Long-Term Debt The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary I C Equity, Including Portion Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
Taxes Payable Current us-gaap/2024 0 0 monetary I C Taxes Payable, Current Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Cost Of Sales Operating Expenses And Other Net 0000059478-25-000132 1 0 monetary D D Cost Of Sales, Operating Expenses, And Other-net Cost Of Sales, Operating Expenses, And Other-net
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment us-gaap/2024 0 0 monetary I C Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
Allowance For Doubtful Accounts Receivable Current us-gaap/2024 0 0 monetary I C Accounts Receivable, Allowance for Credit Loss, Current Amount of allowance for credit loss on accounts receivable, classified as current.
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Deferred Income Tax Assets Net us-gaap/2024 0 0 monetary I D Deferred Income Tax Assets, Net Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Gain Loss On Investments us-gaap/2024 0 0 monetary D C Gain (Loss) on Investments Amount of realized and unrealized gain (loss) on investment.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Payments Of Dividends us-gaap/2024 0 0 monetary D C Payments of Dividends Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Short Term Investments us-gaap/2024 0 0 monetary I D Short-Term Investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Debt Current us-gaap/2024 0 0 monetary I C Debt, Current Amount of debt and lease obligation, classified as current.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Other Operating Activities Cash Flow Statement us-gaap/2024 0 0 monetary D D Other Operating Activities, Cash Flow Statement Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).
Prepaid Expense Current us-gaap/2024 0 0 monetary I D Prepaid Expense, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Stockholders Equity Other us-gaap/2024 0 0 monetary D D Stockholders' Equity, Other This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.
Stock Issued During Period Value Employee Stock Purchase Plan us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Employee Stock Purchase Plan Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
Stock Issued During Period Value Share Based Compensation us-gaap/2024 0 0 monetary D C Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
Stock Repurchase Program Remaining Authorized Repurchase Amount1 us-gaap/2024 0 0 monetary I C Share Repurchase Program, Remaining Authorized, Amount Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Cost Of Goods And Services Sold us-gaap/2024 0 0 monetary D D Cost of Goods and Services Sold The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary D D Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Payments For Proceeds From Other Investing Activities us-gaap/2024 0 0 monetary D C Payments for (Proceeds from) Other Investing Activities Amount of cash (inflow) outflow from investing activities classified as other.
Research And Development Asset Acquired Other Than Through Business Combination Written Off us-gaap/2024 0 0 monetary D D Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.
Depreciation Depletion And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Increase Decrease In Other Operating Capital Net us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Operating Assets and Liabilities, Net Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Payments To Acquire Other Investments us-gaap/2024 0 0 monetary D C Payments to Acquire Other Investments Amount of cash outflow to acquire investments classified as other.
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Liability, Defined Benefit Plan, Noncurrent Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.
Research And Development Expense Excluding Acquired In Process Cost us-gaap/2024 0 0 monetary D D Research and Development Expense (Excluding Acquired in Process Cost) Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Treasury Stock Retired Cost Method Amount us-gaap/2024 0 0 monetary D D Treasury Stock, Retired, Cost Method, Amount Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Sales Rebates And Discounts 0000059478-25-000132 1 0 monetary I C Sales Rebates And Discounts Sales Rebates And Discounts
Dividends Payable Current us-gaap/2024 0 0 monetary I C Dividends Payable, Current Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Nonoperating Income (Expense) The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Other Liabilities Current us-gaap/2024 0 0 monetary I C Other Liabilities, Current Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Treasury Stock Shares Acquired us-gaap/2024 0 0 shares D Treasury Stock, Shares, Acquired Number of shares that have been repurchased during the period and are being held in treasury.
Employee Related Liabilities Current us-gaap/2024 0 0 monetary I C Employee-related Liabilities, Current Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Goodwill us-gaap/2024 0 0 monetary I D Goodwill Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Increase Decrease In Deferred Income Taxes us-gaap/2024 0 0 monetary D C Increase (Decrease) in Deferred Income Taxes The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.
Intangible Assets Net Excluding Goodwill us-gaap/2024 0 0 monetary I D Intangible Assets, Net (Excluding Goodwill) Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Liabilities, Noncurrent Amount of obligation due after one year or beyond the normal operating cycle, if longer.
Long Term Investments us-gaap/2024 0 0 monetary I D Long-Term Investments The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Other Assets Current us-gaap/2024 0 0 monetary I D Other Assets, Current Amount of current assets classified as other.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Payments To Acquire Other Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Other Property, Plant, and Equipment Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.
Proceeds From Payments For Other Financing Activities us-gaap/2024 0 0 monetary D D Proceeds from (Payments for) Other Financing Activities Amount of cash inflow (outflow) from financing activities classified as other.
Stock Repurchase Program Authorized Amount1 srt/2024 0 0 monetary I C Share Repurchase Program, Authorized, Amount Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Amount after tax of other comprehensive income (loss) attributable to parent entity.
Proceeds From Repayments Of Short Term Debt us-gaap/2024 0 0 monetary D D Proceeds from (Repayments of) Short-Term Debt The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
Revenues us-gaap/2024 0 0 monetary D C Revenues Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Additional Paid In Capital Common Stock us-gaap/2024 0 0 monetary I C Additional Paid in Capital, Common Stock Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Payments For Repurchase Of Common Stock us-gaap/2024 0 0 monetary D C Payments for Repurchase of Common Stock The cash outflow to reacquire common stock during the period.
Proceeds From Sale And Maturity Of Other Investments us-gaap/2024 0 0 monetary D D Proceeds from Sale and Maturity of Other Investments The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Common Stock Shares Held In Employee Trust us-gaap/2024 0 0 monetary I D Common Stock, Shares Held in Employee Trust Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Other Receivables Net Current us-gaap/2024 0 0 monetary I D Other Receivables, Net, Current Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
Restructuring Settlement And Impairment Provisions us-gaap/2024 0 0 monetary D D Restructuring, Settlement and Impairment Provisions Amount of restructuring charges, remediation cost, and asset impairment loss.
Stock Issued During Period Shares Employee Stock Purchase Plans us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Employee Stock Purchase Plans Number of shares issued during the period as a result of an employee stock purchase plan.
Treasury Stock Common Value us-gaap/2024 0 0 monetary I D Treasury Stock, Common, Value Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.
Accrued Income Taxes Noncurrent us-gaap/2024 0 0 monetary I C Accrued Income Taxes, Noncurrent Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.
Long Term Debt Noncurrent us-gaap/2024 0 0 monetary I C Long-Term Debt, Excluding Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
Minority Interest us-gaap/2024 0 0 monetary I C Equity, Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
Payments To Acquire In Process Research And Development us-gaap/2024 0 0 monetary D C Payments to Acquire in Process Research and Development The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Treasury Stock Common Shares us-gaap/2024 0 0 shares I Treasury Stock, Common, Shares Number of previously issued common shares repurchased by the issuing entity and held in treasury.
Treasury Stock Shares Retired us-gaap/2024 0 0 shares D Treasury Stock, Shares, Retired Number of shares of common and preferred stock retired from treasury during the period.
Treasury Stock Value Acquired Cost Method us-gaap/2024 0 0 monetary D D Treasury Stock, Value, Acquired, Cost Method Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0000059478-25-000132 2 1 IS 0 H Revenues us-gaap/2024 Revenue (Note 2) 0
0000059478-25-000132 2 3 IS 0 H Cost Of Goods And Services Sold us-gaap/2024 Cost of sales 0
0000059478-25-000132 2 4 IS 0 H Research And Development Expense Excluding Acquired In Process Cost us-gaap/2024 Research and development 0
0000059478-25-000132 2 5 IS 0 H Selling General And Administrative Expense us-gaap/2024 Marketing, selling, and administrative 0
0000059478-25-000132 2 6 IS 0 H Research And Development Asset Acquired Other Than Through Business Combination Written Off us-gaap/2024 Acquired in-process research and development (Note 3) 0
0000059478-25-000132 2 7 IS 0 H Restructuring Settlement And Impairment Provisions us-gaap/2024 Asset impairment, restructuring, and other special charges 0
0000059478-25-000132 2 8 IS 0 H Nonoperating Income Expense us-gaap/2024 Othernet, (income) expense (Note 11) 1
0000059478-25-000132 2 9 IS 0 H Cost Of Sales Operating Expenses And Other Net 0000059478-25-000132 Costs, expenses, and other 0
0000059478-25-000132 2 10 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Income before income taxes 0
0000059478-25-000132 2 11 IS 0 H Income Tax Expense Benefit us-gaap/2024 Income taxes (Note 7) 0
0000059478-25-000132 2 12 IS 0 H Net Income Loss us-gaap/2024 Net income 0
0000059478-25-000132 2 14 IS 0 H Earnings Per Share Basic us-gaap/2024 Basic (in dollars per share) 0
0000059478-25-000132 2 15 IS 0 H Earnings Per Share Diluted us-gaap/2024 Diluted (in dollars per share) 0
0000059478-25-000132 2 17 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Basic (in shares) 0
0000059478-25-000132 2 18 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Diluted (in shares) 0
0000059478-25-000132 3 1 CI 0 H Net Income Loss us-gaap/2024 Net income 0
0000059478-25-000132 3 2 CI 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 Other comprehensive income, net of tax (Note 10) 0
0000059478-25-000132 3 3 CI 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive income 0
0000059478-25-000132 4 3 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents (Note 6) 0
0000059478-25-000132 4 4 BS 0 H Short Term Investments us-gaap/2024 Short-term investments (Note 6) 0
0000059478-25-000132 4 5 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable, net of allowances of $15.5 (2025) and $14.9 (2024) 0
0000059478-25-000132 4 6 BS 0 H Other Receivables Net Current us-gaap/2024 Other receivables 0
0000059478-25-000132 4 7 BS 0 H Inventory Net us-gaap/2024 Inventories (Note 5) 0
0000059478-25-000132 4 8 BS 0 H Prepaid Expense Current us-gaap/2024 Prepaid expenses 0
0000059478-25-000132 4 9 BS 0 H Other Assets Current us-gaap/2024 Other current assets 0
0000059478-25-000132 4 10 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0000059478-25-000132 4 11 BS 0 H Long Term Investments us-gaap/2024 Investments (Note 6) 0
0000059478-25-000132 4 12 BS 0 H Goodwill us-gaap/2024 Goodwill 0
0000059478-25-000132 4 13 BS 0 H Intangible Assets Net Excluding Goodwill us-gaap/2024 Other intangibles, net 0
0000059478-25-000132 4 14 BS 0 H Deferred Income Tax Assets Net us-gaap/2024 Deferred tax assets 0
0000059478-25-000132 4 15 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property and equipment, net of accumulated depreciation of $12,146.9 (2025) and $11,789.0 (2024) 0
0000059478-25-000132 4 16 BS 0 H Other Assets Noncurrent us-gaap/2024 Other noncurrent assets 0
0000059478-25-000132 4 17 BS 0 H Assets us-gaap/2024 Total assets 0
0000059478-25-000132 4 20 BS 0 H Debt Current us-gaap/2024 Short-term borrowings and current maturities of long-term debt 0
0000059478-25-000132 4 21 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0000059478-25-000132 4 22 BS 0 H Employee Related Liabilities Current us-gaap/2024 Employee compensation 0
0000059478-25-000132 4 23 BS 0 H Sales Rebates And Discounts 0000059478-25-000132 Sales rebates and discounts 0
0000059478-25-000132 4 24 BS 0 H Dividends Payable Current us-gaap/2024 Dividends payable 0
0000059478-25-000132 4 25 BS 0 H Taxes Payable Current us-gaap/2024 Short-term income taxes payable 0
0000059478-25-000132 4 26 BS 0 H Other Liabilities Current us-gaap/2024 Other current liabilities 0
0000059478-25-000132 4 27 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0000059478-25-000132 4 29 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Long-term debt 0
0000059478-25-000132 4 30 BS 0 H Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent us-gaap/2024 Accrued retirement benefits (Note 8) 0
0000059478-25-000132 4 31 BS 0 H Accrued Income Taxes Noncurrent us-gaap/2024 Long-term income taxes payable 0
0000059478-25-000132 4 32 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other noncurrent liabilities 0
0000059478-25-000132 4 33 BS 0 H Liabilities Noncurrent us-gaap/2024 Total noncurrent liabilities 0
0000059478-25-000132 4 34 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and Contingencies (Note 9) 0
0000059478-25-000132 4 36 BS 0 H Common Stock Value us-gaap/2024 Common stock 0
0000059478-25-000132 4 37 BS 0 H Additional Paid In Capital Common Stock us-gaap/2024 Additional paid-in capital 0
0000059478-25-000132 4 38 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Retained earnings 0
0000059478-25-000132 4 39 BS 0 H Common Stock Shares Held In Employee Trust us-gaap/2024 Employee benefit trust 1
0000059478-25-000132 4 40 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive loss (Note 10) 0
0000059478-25-000132 4 41 BS 0 H Treasury Stock Common Value us-gaap/2024 Cost of common stock in treasury 1
0000059478-25-000132 4 42 BS 0 H Stockholders Equity us-gaap/2024 Total Eli Lilly and Company shareholders' equity 0
0000059478-25-000132 4 43 BS 0 H Minority Interest us-gaap/2024 Noncontrolling interests 0
0000059478-25-000132 4 44 BS 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Total equity 0
0000059478-25-000132 4 45 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and equity 0
0000059478-25-000132 5 1 BS 1 H Allowance For Doubtful Accounts Receivable Current us-gaap/2024 Accounts receivable, allowances 0
0000059478-25-000132 5 2 BS 1 H Accumulated Depreciation Depletion And Amortization Property Plant And Equipment us-gaap/2024 Property and equipment, accumulated depreciation 0
0000059478-25-000132 6 13 EQ 0 H Common Stock Shares Issued us-gaap/2024 Beginning balance (in shares) 0
0000059478-25-000132 6 14 EQ 0 H Treasury Stock Common Shares us-gaap/2024 Beginning balance (in shares) 0
0000059478-25-000132 6 15 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Beginning balance 0
0000059478-25-000132 6 16 EQ 0 H Profit Loss us-gaap/2024 Net income (loss) 0
0000059478-25-000132 6 17 EQ 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 Other comprehensive income, net of tax 0
0000059478-25-000132 6 18 EQ 0 H Treasury Stock Shares Retired us-gaap/2024 Retirement of treasury shares (in shares) 1
0000059478-25-000132 6 19 EQ 0 H Treasury Stock Retired Cost Method Amount us-gaap/2024 Retirement of treasury shares 1
0000059478-25-000132 6 20 EQ 0 H Treasury Stock Shares Acquired us-gaap/2024 Purchase of treasury shares (in shares) 0
0000059478-25-000132 6 21 EQ 0 H Treasury Stock Value Acquired Cost Method us-gaap/2024 Purchase of treasury shares 1
0000059478-25-000132 6 22 EQ 0 H Stock Issued During Period Shares Employee Stock Purchase Plans us-gaap/2024 Issuance of stock under employee stock plans, net (in shares) 0
0000059478-25-000132 6 23 EQ 0 H Stock Issued During Period Value Employee Stock Purchase Plan us-gaap/2024 Issuance of stock under employee stock plans, net 0
0000059478-25-000132 6 24 EQ 0 H Stock Issued During Period Value Share Based Compensation us-gaap/2024 Stock-based compensation 0
0000059478-25-000132 6 25 EQ 0 H Stockholders Equity Other us-gaap/2024 Other 1
0000059478-25-000132 6 26 EQ 0 H Common Stock Shares Issued us-gaap/2024 Ending balance (in shares) 0
0000059478-25-000132 6 27 EQ 0 H Treasury Stock Common Shares us-gaap/2024 Ending balance (in shares) 0
0000059478-25-000132 6 28 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Ending balance 0
0000059478-25-000132 7 1 EQ 1 H Stock Repurchase Program Remaining Authorized Repurchase Amount1 us-gaap/2024 Stock repurchase program, remaining authorized amount 0
0000059478-25-000132 7 2 EQ 1 H Stock Repurchase Program Authorized Amount1 srt/2024 Stock repurchase program, authorized amount 0
0000059478-25-000132 8 2 CF 0 H Net Income Loss us-gaap/2024 Net income 0
0000059478-25-000132 8 4 CF 0 H Depreciation Depletion And Amortization us-gaap/2024 Depreciation and amortization 0
0000059478-25-000132 8 5 CF 0 H Increase Decrease In Deferred Income Taxes us-gaap/2024 Change in deferred income taxes 1
0000059478-25-000132 8 6 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation expense 0
0000059478-25-000132 8 7 CF 0 H Gain Loss On Investments us-gaap/2024 Net investment (gains) losses 1
0000059478-25-000132 8 8 CF 0 H Research And Development Asset Acquired Other Than Through Business Combination Written Off us-gaap/2024 Acquired in-process research and development 0
0000059478-25-000132 8 9 CF 0 H Increase Decrease In Other Operating Capital Net us-gaap/2024 Other changes in operating assets and liabilities, net of acquisitions and divestitures 1
0000059478-25-000132 8 10 CF 0 H Other Operating Activities Cash Flow Statement us-gaap/2024 Other operating activities, net 0
0000059478-25-000132 8 11 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net Cash Provided by Operating Activities 0
0000059478-25-000132 8 13 CF 0 H Payments To Acquire Other Property Plant And Equipment us-gaap/2024 Purchases of property and equipment 1
0000059478-25-000132 8 14 CF 0 H Proceeds From Sale And Maturity Of Other Investments us-gaap/2024 Proceeds from sales of and distributions from noncurrent investments 0
0000059478-25-000132 8 15 CF 0 H Payments To Acquire Other Investments us-gaap/2024 Purchases of noncurrent investments 1
0000059478-25-000132 8 16 CF 0 H Payments To Acquire In Process Research And Development us-gaap/2024 Purchases of in-process research and development 1
0000059478-25-000132 8 17 CF 0 H Payments For Proceeds From Other Investing Activities us-gaap/2024 Other investing activities, net 1
0000059478-25-000132 8 18 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net Cash Used for Investing Activities 0
0000059478-25-000132 8 20 CF 0 H Payments Of Dividends us-gaap/2024 Dividends paid 1
0000059478-25-000132 8 21 CF 0 H Proceeds From Repayments Of Short Term Debt us-gaap/2024 Net change in short-term borrowings 0
0000059478-25-000132 8 22 CF 0 H Proceeds From Issuance Of Long Term Debt us-gaap/2024 Proceeds from issuance of long-term debt 0
0000059478-25-000132 8 23 CF 0 H Payments For Repurchase Of Common Stock us-gaap/2024 Purchases of common stock 1
0000059478-25-000132 8 24 CF 0 H Proceeds From Payments For Other Financing Activities us-gaap/2024 Other financing activities, net 0
0000059478-25-000132 8 25 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net Cash Provided by (Used for) Financing Activities 0
0000059478-25-000132 8 26 CF 0 H Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Effect of exchange rate changes on cash and cash equivalents 0
0000059478-25-000132 8 27 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net decrease in cash and cash equivalents 0
0000059478-25-000132 8 28 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash and cash equivalents at January 1 0
0000059478-25-000132 8 29 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash and Cash Equivalents at March 31 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.